Ketamine for Treatment-Resistant Depression: A Clinical Guide
Dr. Martin Wyss
PsiHub Research
This article was drafted with AI assistance and editorially reviewed by Dr. Martin Wyss.
Ketamine for Treatment-Resistant Depression: A Clinical Guide
Treatment-resistant depression (TRD)—defined as failure to respond to at least two adequate antidepressant trials—affects approximately 30% of all people diagnosed with major depressive disorder. For this population, the standard antidepressant toolkit is exhausted, and the human cost is immense: TRD patients account for a disproportionate share of depression-related disability, healthcare costs, and suicide risk.
Ketamine has transformed the TRD landscape. Unlike every conventional antidepressant, which requires weeks to achieve therapeutic effect, ketamine produces measurable antidepressant responses within hours—a property that makes it uniquely valuable for patients in acute crisis.
Key Takeaways
- Ketamine produces antidepressant response in 50–70% of TRD patients, typically within 24 hours
- IV ketamine (0.5 mg/kg over 40 min) remains the gold standard; intranasal esketamine (Spravato) is FDA-approved
- Effects are transient without maintenance dosing; optimal maintenance schedules vary by patient
- Mechanism involves NMDA receptor blockade, glutamate burst, and BDNF/mTOR cascade
- Dissociative side effects are manageable; abuse potential requires patient selection care
Mechanisms of Rapid Antidepressant Action
Ketamine's rapid antidepressant effect is mediated through a cascade distinct from conventional monoamine-based antidepressants:
This mechanism produces structural changes in hours rather than the weeks required by SSRIs to achieve receptor sensitivity changes.
Clinical Protocols
IV Ketamine: The standard protocol involves 0.5 mg/kg infused over 40 minutes, typically administered twice weekly for 3 weeks (6 infusions). Response rates range from 50–70% in TRD populations. Maintenance infusions (every 2–4 weeks) are often required to sustain response.
Intranasal Esketamine (Spravato): The S-enantiomer of ketamine, approved by the FDA in 2019 for TRD and in 2020 for MDD with acute suicidal ideation. Self-administered under clinical supervision (84 mg per session), esketamine requires a certified healthcare setting due to monitoring requirements.
Response Rates and Durability
Meta-analyses (Fond et al., 2014; Murrough et al., 2013) consistently show response rates of 50–70% after a single infusion, with effect sizes (Cohen's d ≈ 0.8–1.2) substantially exceeding conventional antidepressants. However, without maintenance dosing, effects typically wane within 1–2 weeks.
This durability gap is ketamine's primary limitation and the focus of ongoing research: how to extend or convert ketamine's acute effects into sustained remission.
Explore more: Ketamine · Depression · Browse studies · Treatment protocols
References
Share this post